Wilson's disease

Lancet

Volumn 369, Issue 9559, 2007, Pages 397-408

  Ala, Aftab ^a,b   Walker, Ann P ^a   Ashkan, Keyoumars ^c   Dooley, James S ^a   Schilsky, Michael L ^d  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b FRIMLEY PARK HOSPITAL   (United Kingdom)

^c NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^d WEILL CORNELL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ALPHA TOCOPHEROL; CERULOPLASMIN; CHELATING AGENT; COPPER; DIMERCAPROL; GLUCONATE ZINC; PENICILLAMINE; PYRIDOXINE; TETRATHIOMOLYBDATE AMMONIUM; TRIENTINE; ZINC; ZINC ACETATE; ZINC SULFATE;

AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; APHTHOUS STOMATITIS; APLASIA; BONE MARROW SUPPRESSION; CHELATION THERAPY; CLINICAL FEATURE; CLINICAL TRIAL; DIAGNOSTIC APPROACH ROUTE; DIET; DRUG DOSE REDUCTION; DRUG HYPERSENSITIVITY; DYSPEPSIA; ELASTOSIS; FEVER; HEPATIC ENCEPHALOPATHY; HUMAN; KIDNEY DISEASE; LEUKOPENIA; LIVER HEMOSIDEROSIS; LIVER TRANSPLANTATION; LUPUS LIKE SYNDROME; LYMPHADENOPATHY; NEPHROTOXICITY; NEUROLOGIC DISEASE; NEUTROPENIA; PANCYTOPENIA; PATHOGENESIS; PATHOPHYSIOLOGY; PATIENT MONITORING; PRIORITY JOURNAL; PROTEINURIA; RASH; REVIEW; SCREENING TEST; SIDE EFFECT; SIDEROBLASTIC ANEMIA; THROMBOCYTOPENIA; URINARY EXCRETION; WILSON DISEASE;

EID: 33846582913     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(07)60196-2     Document Type: Review

References (118)

1. Wilson S. Progressive lenticular degeneration: a familial nervous disease associated with cirrhosis of the liver. Brain 34 (1912) 20-509
2. Alt E., Sternlieb I., and Goldfischer S. The cytopathology of metal overload. Int Rev Exp Pathol 31 (1990) 165-188
3. Sternlieb I. Mitochondrial and fatty changes in hepatocytes of patients with Wilson's disease. Gastroenterology 55 (1968) 354-367
4. Schilsky M., Scheinberg I., and Sternlieb I. Prognosis of Wilsonian chronic active hepatitis. Gastroenterology 100 (1991) 762-767
5. Muller T., Langner C., Fuchsbichler A., et al. Immunohistochemical analysis of Mallory bodies in Wilsonian and non-Wilsonian hepatic copper toxicosis. Hepatology 39 (2004) 963-969
6. Strand S., Hofmann W., Grambihler A., et al. Hepatic failure and liver cell damage in acute Wilson's disease involve CD95 (APO-1/Fas) mediated apoptosis. Nat Med 4 (1998) 588-593
7. Goldfischer S., and Sternlieb I. Changes in the distribution of hepatic copper in relation to the progression of Wilson's disease (hepatolenticular degeneration). Am J Pathol 53 (1968) 883-901
8. Frydman M., Bonne-Tamir B., Farrer L., et al. Assignment of the gene for Wilson disease to chromosome 13: linkage to the esterase D locus. Proc Natl Acad Sci USA 82 (1985) 1819-1821
9. Bull P., Thomas G., Rommens J., Forbes J., and Cox D. The Wilson disease gene is a putative copper transporting P-type ATPase similar to the Menkes gene. Nat Genet 5 (1993) 327-337
10. Tanzi R., Petrukhin K., Chernov I., et al. The Wilson disease gene is a copper transporting ATPase with homology to the Menkes disease gene. Nat Genet 5 (1993) 344-350
11. Yamaguchi Y., Heiny M., and Gitlin J. Isolation and characterization of a human liver cDNA as a candidate gene for Wilson disease. Biochem Biophys Res Commun 197 (1993) 271-277
12. Roelofsen H., Wolters H., Van Luyn M., Miura N., Kuipers F., and Vonk R. Copper-induced apical trafficking of ATP7B in polarized hepatoma cells provides a mechanism for biliary copper excretion. Gastroenterology 119 (2000) 782-793
13. Schaefer M., Roelofsen H., Wolters H., et al. Localization of the Wilson's disease protein in human liver. Gastroenterology 117 (1999) 1380-1385
14. Huster D., Hoppert M., Lutsenko S., et al. Defective cellular localization of mutant ATP7B in Wilson's disease patients and hepatoma cell lines. Gastroenterology 124 (2003) 335-345
15. Tsivkovskii R., Efremov R., and Lutsenko S. The role of the invariant His-1069 in folding and function of the Wilson's disease protein, the human copper-transporting ATPase ATP7B. J Biol Chem 278 (2003) 13302-13308
16. Lee J., Prohaska J., and Thiele D. Essential role for mammalian copper transporter Ctr1 in copper homeostasis and embryonic development. Proc Natl Acad Sci USA 98 (2001) 6842-6847
17. Kuo Y., Zhou B., Cosco D., and Gitschier J. The copper transporter CTR1 provides an essential function in mammalian embryonic development. Proc Natl Acad Sci USA 98 (2001) 6836-6841
18. van Dongen E., Klomp L., and Merkx M. Copper-dependent protein-protein interactions studied by yeast two-hybrid analysis. Biochem Biophys Res Commun 323 (2004) 789-795
19. Tao T., Liu F., Klomp L., Wijmenga C., and Gitlin J. The copper toxicosis gene product Murr1 directly interacts with the Wilson disease protein. J Biol Chem 278 (2003) 41593-41596
20. Coronado V., Bonneville J., Nazer H., Roberts E., and Cox D. COMMD1 (MURR1) as a candidate in patients with copper storage disease of undefined etiology. Clin Genet 68 (2005) 548-551
21. Safaei R., and Howell S. Copper transporters regulate the cellular pharmacology and sensitivity to Pt drugs. Crit Rev Oncol Hematol 3 (2005) 13-23
22. Vrabelova S., Letocha O., Borsky M., and Kozak L. Mutation analysis of the ATP7B gene and genotype/phenotype correlation in 227 patients with Wilson disease. Mol Genet Metab 86 (2005) 277-285
23. Wu Z., Wang N., Lin M., Fang L., Murong S., and Yu L. Mutation analysis and the correlation between genotype and phenotype of Arg778Leu mutation in chinese patients with Wilson disease. Arch Neurol 58 (2001) 971-976
24. Gu Y., Kodama H., Du S., Gu Q., Sun H., and Ushijima H. Mutation spectrum and polymorphisms in ATP7B identified on direct sequencing of all exons in Chinese Han and Hui ethnic patients with Wilson's disease. Clin Genet 64 (2003) 479-484
25. Kumar S., Thapa B., Kaur G., and Prasad R. Identification and molecular characterization of 18 novel mutations in the ATP7B gene from Indian Wilson disease patients: genotype. Clin Genet 67 (2005) 443-445
26. Al Jumah M., Majumdar R., Al Rajeh S., et al. A clinical and genetic study of 56 Saudi Wilson disease patients: identification of Saudi-specific mutations. Eur J Neurol 11 (2004) 121-124
27. Stapelbroek J., Bollen C., van Amstel J., et al. The H1069Q mutation in ATP7B is associated with late and neurologic presentation in Wilson disease: results of a meta-analysis. J Hepatol 41 (2004) 758-763
28. Butler P., McIntyre N., and Mistry P. Molecular diagnosis of Wilson disease. Mol Genet Metab 72 (2001) 223-230
29. Bobba A., Marra E., Fathallah D., and Giannattasio S. Non-radioactive detection of five common microsatellite markers for ATP7B gene in Wilson disease patients. Mol Cell Probes 17 (2003) 271-274
30. Wilson D., Phillips M., Cox D., and Roberts E. Severe hepatic Wilson's disease in preschool-aged children. J Pediatr 137 (2000) 719-722
31. Ala A., Borjigin J., Rochwarger A., and Schilsky M. Wilson disease in septuagenarian siblings: raising the bar for diagnosis. Hepatology 41 (2005) 668-670
32. Perri R., Hahn S., Ferber M., and Kamath P. Wilson Disease-keeping the bar for diagnosis raised. Hepatology 42 (2005) 974
33. Schmidt H. Role of genetic testing in liver transplantation for Wilson's disease. Transplant Proc 35 (2003) 2078-2079
34. Margulies M., Egholm M., Altman W., et al. Genome sequencing in microfabricated high-density picolitre reactors. Nature 437 (2005) 376-380
35. Ostapowicz G., Fontana R., Schiodt F., et al. U.S. Acute Liver Failure Study Group. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med 137 (2002) 947-954
36. Tissieres P., Chevret L., Debray D., and Devictor D. Fulminant Wilson's disease in children: appraisal of a critical diagnosis. Pediatr Crit Care Med 4 (2003) 338-343
37. Sallie R., Katsiyiannakis L., Baldwin D., et al. Failure of simple biochemical indexes to reliably differentiate fulminant Wilson's disease from other causes of fulminant liver failure. Hepatology 16 (1992) 1206-1211
38. Saito T. Presenting symptoms and natural history of Wilson disease. Eur J Pediatr 146 (1987) 261-265
39. Medici V., Mirante V., Fassati L., et al. Monotematica AISF 2000 OLT Study Group. Liver transplantation for Wilson's disease: The burden of neurological and psychiatric disorders. Liver Transpl 11 (2005) 1056-1063
40. Santos R., Alissa F., Reyes J., Teot L., and Ameen N. Fulminant hepatic failure: Wilson's disease or autoimmune hepatitis? Implications for transplantation. Pediatr Transplant 9 (2005) 112-116
41. Walshe J., Waldenstrom E., Sams V., Nordlinder H., and Westermark K. Abdominal malignancies in patients with Wilson's disease. QJM 96 (2003) 657-662
42. Wilkinson M., Portmann B., and Williams R. Wilson's disease and hepatocellular carcinoma: possible protective role of copper. Gut 24 (1983) 767-771
43. Wiebers D., Hollenhorst R., and Goldstein N. The ophthalmologic manifestations of Wilson's disease. Mayo Clin Proc 52 (1977) 409-416
44. Cairns J., Williams H., and Walshe J. "Sunflower cataract" in Wilson's disease. BMJ 3 (1969) 95-96
45. Esmaeli B., Burnstine M., Martonyi C., Sugar A., Johnson V., and Brewer G. Regression of Kayser-Fleischer rings during oral zinc therapy: correlation with systemic manifestations of Wilson's disease. Cornea 15 (1996) 582-588
46. Schilsky M., Scheinberg I., and Sternlieb I. Liver transplantation for Wilson's disease: indications and outcome. Hepatology 19 (1994) 583-587
47. Frommer D., Morris J., Sherlock S., Abrams J., and Newman S. Kayser-Fleischer-like rings in patients without Wilson's disease. Gastroenterology 72 (1977) 1331-1335
48. Fleming C., Dickson E., Wahner H., Hollenhorst R., and McCall J. Pigmented corneal rings in non-Wilsonian liver disease. Ann Intern Med 86 (1977) 285-288
49. Richard J., and Friendly D. Ocular findings in pediatric systemic disease. Pediatr Clin North Am 30 (1983) 1123-1144
50. Walshe J. Wilson's disease. The presenting symptoms. Arch Dis Child 37 (1962) 253-256
51. Svetel M., Kozic D., Stefanova E., Semnic R., Dragasevic N., and Kostic V. Dystonia in Wilson's disease. Mov Disord 16 (2001) 719-723
52. del Rosario M., Davis M., and Chong S. Wobbly handwriting. Lancet 351 (1998) 336
53. Chu N. Clinical, CT and evoked potential manifestations in Wilson's disease with cerebral white matter involvement. Clin Neurol Neurosurg 91 (1989) 45-51
54. Bax R., Hassler A., Luck W., et al. Cerebral manifestation of Wilson's disease successfully treated with liver transplantation. Neurology 51 (1998) 863-865
55. Walter G., and Lyndon B. Depression in hepatolenticular degeneration (Wilson's disease). Aust N Z J Psychiatry 31 (1997) 880-882
56. Chu N., Chu C., Tu S., and Huang C. EEG spectral analysis and topographic mapping in Wilson's disease. J Neurol Sci 106 (1991) 1-9
57. Dening T., and Berrios G. Wilson's disease: a longitudinal study of psychiatric symptoms. Biol Psychiatry 28 (1990) 255-265
58. Dening T., and Berrios G. Wilson's disease. Psychiatric symptoms in 195 cases. Arch Gen Psychiatry 46 (1989) 1126-1134
59. Davis E., and Borde M. Wilson's disease and catatonia. Br J Psychiatry 162 (1993) 256-259
60. Oder W., Grimm G., Kollegger H., Ferenci P., Schneider B., and Deecke L. Neurological and neuropsychiatric spectrum of Wilson's disease: a prospective study of 45 cases. J Neurol 238 (1991) 281-287
61. King A., Walshe J., Kendall B., et al. Cranial MR imaging in Wilson's disease. AJR Am J Roentgenol 167 (1996) 1579-1584
62. Sinha S., Taly A., Ravishankar S., et al. Wilson's disease: cranial MRI observations and clinical correlation. Neuroradiology 48 (2006) 613-621
63. Kozic D., Svetel M., Petrovic B., Dragasevic N., Semnic R., and Kostic V. MR imaging of the brain in patients with hepatic form of Wilson's disease. Eur J Neurol 10 (2003) 587-592
64. Page R., Davie C., MacManus D., et al. Clinical correlation of brain MRI and MRS abnormalities in patients with Wilson disease. Neurology 63 (2004) 638-643
65. Opalski A. Type special de cellules neurologiques dans la degenerescence lenticulaire progressive. Z Gesamte Neurol Psychiatrie 124 (1930) 420
66. Scheinberg I., and Sternlieb I. Wilson's disease (1984), WB Saunders, Philadelphia
67. Medalia A., Galynker I., and Scheinberg I. The interaction of motor, memory, and emotional dysfunction in Wilson's disease. Biol Psychiatry 31 (1992) 823-826
68. Siesling S., Zwinderman A., van Vugt J., Kieburtz K., and Roos R. A shortened version of the motor section of the Unified Huntington's Disease Rating Scale. Mov Disord 12 (1997) 229-234
69. Golding D., and Walshe J. Arthropathy of Wilson's disease. Study of clinical and radiological features in 32 patients. Ann Rheum Dis 36 (1977) 99-111
70. Xie Y., Zhang X., Xu X., Zhang Z., and Feng Y. Radiologic study of 42 cases of Wilson disease. Skeletal Radiol 13 (1985) 114-119
71. Kuan P. Cardiac Wilson's disease. Chest 91 (1987) 579-583
72. Factor S., Cho S., Sternlieb I., Scheinberg I., and Goldfischer S. The cardiomyopathy of Wilson's disease. Myocardial alterations in nine cases. Virchows Arch A Pathol Anat Histol 397 (1982) 301-311
73. Carpenter T., Carnes Jr. D., and Anast C. Hypoparathyroidism in Wilson's disease. N Engl J Med 309 (1983) 873-877
74. Yuzbasiyan-Gurkan V., Brewer G., Abrams G., Main B., and Giacherio D. Treatment of Wilson's disease with zinc, V-changes in serum levels of lipase, amylase, and alkaline phosphatase in patients with Wilson's disease. J Lab Clin Med 114 (1989) 520-526
75. Frydman M., Kauschansky A., Bonne-Tamir B., Nassar F., and Homburg R. Assessment of the hypothalamic-pituitary-testicular function in male patients with Wilson's disease. J Androl 12 (1991) 180-184
76. Sinha S., Taly A., Prashanth L., Arunodaya G., and Swamy H. Successful pregnancies and abortions in symptomatic and asymptomatic Wilson's disease. J Neurol Sci 217 (2004) 37-40
77. Kaushansky A., Frydman M., Kaufman H., and Homburg R. Endocrine studies of the ovulatory disturbances in Wilson's disease (hepatolenticular degeneration). Fertil Steril 47 (1987) 270-273
78. Kalra V., Mahajan S., and Kesarwani P. Rare presentation of Wilson's disease: a case report. Int Urol Nephrol 36 (2004) 289-291
79. Sozeri E., Feist D., Ruder H., and Scharer K. Proteinuria and other renal functions in Wilson's disease. Pediatr Nephrol 11 (1997) 307-311
80. Ferenci P., Caca K., Loudianos G., et al. Diagnosis and phenotypic classification of Wilson disease. Liver Int 23 (2003) 139-142
81. Roberts E., and Schilsky M. A practice guideline on Wilson disease. Hepatology 37 (2003) 1475-1492
82. Steindl P., Ferenci P., Dienes H., et al. Wilson's disease in patients with liver disease: a diagnostic challenge. Gastroenterology 113 (1997) 212-218
83. Menkes J. Menkes disease and Wilson disease: two sides of the same copper coin. Part I:Menkes disease. Eur J Paediatr Neurol 3 (1999) 147-158
84. Edwards C., Williams D., and Cartwright G. Hereditary hypoceruloplasminemia. Clin Genet 15 (1979) 311-316
85. Ferenci P., Steindl-Munda P., Vogel W., et al. Diagnostic value of quantitative hepatic copper determination in patients with Wilson's Disease. Clin Gastroenterol Hepatol 3 (2005) 811-818
86. Tu J., and Blackwell R. Studies on levels of penicillamine-induced cupriuresis in heterozygotes of Wilson's disease. Metabolism 16 (1967) 507-513
87. Gow P., Smallwood R., Angus P., et al. Diagnosis of Wilson's disease: an experience over three decades. Gut 46 (2000) 415-419
88. Frommer D. Urinary copper excretion and hepatic copper concentrations in liver disease. Digestion 21 (1981) 169-178
89. Martins da Costa C., Baldwin D., Portmann B., Lolin Y., Mowat A., and Mieli-Vergani G. Value of urinary copper excretion after penicillamine challenge in the diagnosis of Wilson's disease. Hepatology 15 (1992) 609-615
90. Walshe J. Wilson's disease. New oral therapy. Lancet 267 (1956) 25-26
91. Walshe J. The management of penicillamine nephropathy in Wilson's disease. A new chelating agent. Lancet 294 (1969) 1401-1402
92. Brewer G., Hedera P., Kluin K., et al. Treatment of Wilson's disease with ammonium tetrathiomolybdate III. Initial therapy in a total of 55 neurologically affected patients and follow-up with zinc therapy. Arch Neurol 60 (2003) 379-385
93. Brewer G., Dick R., Johnson V., et al. Treatment of Wilson's disease with zinc: XV. Long-term follow-up studies. J Lab Clin Med 132 (1998) 264-278
94. Brewer G., Askari F., Lorincz M., et al. Treatment of Wilson Disease with Ammonium Tetrathiomolybdate. IV. Comparison of tetrathiomolybdate and trientine in a double-blind study of treatment of the neurologic presentation of Wilson disease. Arch Neurol 63 (2006) 521-527
95. Sternlieb I., and Scheinberg I. Prevention of Wilson's in asymptomatic patients: prophylaxis of Wilson's disease. N Engl J Med 278 (1968) 352-355
96. Scheinberg I., and Sternlieb I. Wilson's disease. Major problems in Internal Medicine, XXIII (1984), WB Saunders, Philadelphia
97. Gibbs K., and Walshe J. Penicillamine and pyridoxine requirements in man. Lancet 309 (1966) 175-179
98. Walshe J., and Yealland M. Chelation treatment of neurological Wilson's disease. Q J Med 86 (1993) 197-204
99. Brewer G., Terry C., Aisen A., and Hill G. Worsening of neurologic syndrome in patients with Wilson's disease with initial penicillamine therapy. Arch Neurol 44 (1987) 490-493
100. Schilsky M. Treatment of Wilson's disease: what are the relative roles of penicillamine, trientine, and zinc supplementation?. Curr Gastroenterol Rep 3 (2001) 54-59
101. Ferenci P. Review article: diagnosis and current therapy of Wilson's disease. Aliment Pharmacol Ther 19 (2004) 157-165
102. Askari F., Greenson, Dick R., Johnson V., and Brewer G. Treatment of Wilson's disease with zinc. XVIII. Initial treatment of the hepatic decompensation presentation with trientine and zinc. J Lab Clin Med 142 (2003) 385-390
103. Brewer G. Neurologically presenting Wilson's Disease: epidemiology, pathophysiology and treatment. CNS Drugs 19 (2005) 185-192
104. Czlonkowska A., Gajda J., and Rodo M. Effects of long-term treatment in Wilson's disease with D-penicillamine and zinc sulphate. J Neurol 243 (1996) 269-273
105. Prashanth L., Taly A., Sinha S., et al. Prognostic factors in patients presenting with severe neurological forms of Wilson's disease. Q J Med 98 (2005) 557-563
106. Sinha S., Christopher R., Arunodaya G., et al. Is low serum tocopherol in Wilson's disease a significant symptom?. J Neurol Sci 228 (2005) 121-123
107. Barthel H., Hermann W., Kluge R., et al. Concordant pre- and postsynaptic deficits of dopaminergic neurotransmission in neurologic Wilson disease. Am J Neuroradiol 24 (2003) 234-238
108. Jeon B., Kim J., Jeong J., et al. Dopamine transporter imaging with [123I]-beta-CIT demonstrates presynaptic nigrostriatal dopaminergic damage in Wilson's disease. J Neurol Neurosurg Psychiatry 65 (1998) 60-64
109. Podgaetz E., Chan C., et al. Liver transplantation for Wilson s disease: our experience with review of the literature. Ann Hepatol 2 (2003) 131-134
110. Emre S., Atillasoy E., Ozdemir S., et al. Orthotopic liver transplantation for Wilson's disease: a single center experience. Liver Transpl 72 (2001) 1232-1236
111. Sen S., Felldin M., Steiner C., et al. Albumin dialysis and Molecular Adsorbents Recirculating System (MARS) for acute Wilson's disease. Liver Transpl 8 (2002) 962-967
112. Tamura S., Sugawara Y., Kishi Y., Akamatsu N., Kaneko J., and Makuuchi M. Living-related liver transplantation for Wilson's disease. Clin Transplant 19 (2005) 483-486
113. Stracciari A., Tempestini A., Borghi A., and Guarino M. Effect of liver transplantation on neurological manifestations in Wilson disease. Arch Neurol 57 (2000) 384-386
114. Guarino M., Stracciari A., D'Alessandro R., and Pazzaglia P. No neurological improvement after liver transplantation for Wilson's disease. Acta Neurol Scand 92 (1995) 405-408
115. Terada K., Aiba N., Yang X., et al. Biliary excretion of copper in LEC rat after introduction of copper transporting P-type ATPase, ATP7B. FEBS Lett 448 (1999) 53-56
116. Irani A., Malhi H., Slehria S., et al. Correction of liver disease following transplantation of normal rat hepatocytes into Long-Evans Cinnamon rats modeling Wilson's disease. Mol Ther 3 (2001) 302-309
117. Ha-Hao D., Merle U., Hofmann C., et al. Chances and shortcomings of adenovirus-mediated ATP7B gene transfer in Wilson disease: proof of principle demonstrated in a pilot study with LEC rats. Z Gastroenterol 40 (2002) 209-216
118. Schilsky M. Wilson disease: new insights into pathogenesis, diagnosis, and future therapy. Curr Gastroenterol Rep 7 (2005) 26-31